LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajanikant Gulabdas Patel LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement with respect to the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2021. LINCOLN PHARMACEUTICALS LTD. - 531633 - Financial Results Of The Company
To Consider and approved un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and nine months ended on December 31, 2021. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for Outcome Of Board Meeting
OUTCOME OF BOARD MEETING LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Consider And Approve The Un-Audited Financial Results Of The Company.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 ,inter alia, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended on December 31, 2021 along with any other business, if any. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
As per letter attached LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholding for the Period Ended December 31, 2021
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) for the Quarter Ended December 31, 2021. LINCOLN PHARMACEUTICALS LTD. - 531633 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NIREN DESAIDesignation :- Company Secretary and Compliance Officer